RCS - ReNeuron Group plc - Jefferies 2019 Global Healthcare Conference

ReNeuronAnnouncement

31/05/2019 07:05

RNS Number : 7207A
ReNeuron Group plc
31 May 2019
 


 



 
31 May 2019


 
AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Jefferies 2019 Global Healthcare Conference
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company's management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City.
 
For further information on the conference, please visit the following link: Jefferies 2019 Global Healthcare Conference 
 
ENDS
 



Contacts:
 
ReNeuron


 
 
+44 (0) 20 3819 8400




Olav Hellebø, Chief Executive Officer




Michael Hunt, Chief Financial Officer




 
Buchanan (UK Media/Investor Relations)


 
+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham




 
Argot Partners (US Media/Investor Relations)
Claudia Styslinger, David Rosen


 
+1 212 600 1902 or email
claudia@argotpartners.com




 


 




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison


+44 (0) 20 7710 7600
 




 
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor


 
+44 (0) 20 7496 3000




 


 



About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRACKDDPPBKKNPN